Get started
Author

Xujuan Wang

Col1A1 as a new decoder of clinical features and immune microenvironment in ovarian cancer
2025 · Xiao Xiao, Fangyi Long, et al. · Frontiers in Immunology · 17
PDF
Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial
2025 · Jieqiong Liu, Chuangui Song, et al. · Clinical Cancer Research · 7
PDF
Efficacy and safety of margetuximab plus chemotherapy vs. trastuzumab plus chemotherapy in Chinese patients with pretreated HER2-positive advanced metastatic breast cancer: results from a randomized, open-label, multicenter, phase II bridging study
2022 · Qingyuan Zhang, Quchang Ouyang, et al. · Translational Breast Cancer Research · 6
PDF
Abstract P5-16-04: Preliminary safety and efficacy results of KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with KN026 (a HER2-targeted bispecific antibody) in patients with metastatic HER2-positive breast cancer: A phase II trial
2022 · Jieqiong Liu, Chuangui Song, et al. · Cancer Research · 4
8MW0511, a novel, long-acting granulocyte-colony stimulating factor fusion protein for the prevention of chemotherapy-induced neutropenia: final results from the phase III clinical trial
2025 · Biyun Wang, Xiuchun Chen, et al. · Breast Cancer Research · 3
PDF
Abstract PS8-06: A randomized, open-label phase III study comparing disitamab vedotin (an anti-HER2 monoclonal antibody-MMAE conjugate) with lapatinib plus capecitabine in patients with HER2-positive, advanced breast cancer with liver metastasis
2025 · Jiayu Wang, Quchang Ouyang, et al. · Clinical Cancer Research · 2
Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer
2026 · Jiayu Wang, Huiping Li, et al. · New England Journal of Medicine · 1
Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial
2026 · Peng Yuan, Yunjiang Liu, et al. · JAMA Oncology · 1
Izalontamab brengitecan for HR+/HER2– breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial
2026 · Bo Lan, Yehui Shi, et al. · The Lancet
Neoadjuvant Pertuzumab Biosimilar HLX11 versus Reference Pertuzumab for Early-Stage or Locally Advanced Breast Cancer: A Phase III Equivalence Trial
2026 · Jin Zhang, Jinhai Zhu, et al. · Clinical Cancer Research
Disitamab vedotin for HER2-positive breast cancer with liver metastases: phase 3 results from the RC48-C006 phase 2/3 trial
2026 · Jiayu Wang, Quchang Ouyang, et al. · Nature Communications
PDF
Efficacy and safety of SPH4336 plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer with brain metastases: A multicenter, single-arm, phase II study.
2026 · Kuikui Jiang, Shusen Wang, et al. · Journal of Clinical Oncology
Fovinaciclib versus placebo combined with fulvestrant for advanced breast cancer after endocrine therapy: A randomized, double-blind phase 3 trial.
2026 · Xichun Hu, Yunjiang Liu, et al. · Journal of Clinical Oncology
PDF
Supplementary Table S5 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial
2025 · Jieqiong Liu, Chuangui Song, et al.
Supplementary Table S4 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial
2025 · Jieqiong Liu, Chuangui Song, et al.
Supplementary Table S3 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial
2025 · Jieqiong Liu, Chuangui Song, et al.
Data from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial
2025 · Jieqiong Liu, Chuangui Song, et al.
Supplementary Table S2 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial
2025 · Jieqiong Liu, Chuangui Song, et al.
Supplementary Data S1 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial
2025 · Jieqiong Liu, Chuangui Song, et al.
Supplementary Table S1 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial
2025 · Jieqiong Liu, Chuangui Song, et al.
Abstract PO1-29-03: Efficacy, Safety, and Immunogenicity of TQ-B211 (a Trastuzumab Biosimilar) Plus Docetaxel versus Herceptin® Plus Docetaxel for HER2-positive Metastatic Breast Cancer: a Double-blind, Randomised, Multicenter, Phase 3 Trial
2024 · Xichun Hu, Qingyuan Zhang, et al. · Cancer Research
Works count: 22
Citation count: 41
H-index: 4
I10-index: 1
Year
Topic
Type